These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33031058)

  • 1. SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients.
    Li P; Xiao J; Zhou B; Wei J; Luo J; Chen W
    Aging (Albany NY); 2020 Oct; 12(19):19316-19324. PubMed ID: 33031058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Harbin LM; Lin N; Ueland FR; Kolesar JM
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762518
    [No Abstract]   [Full Text] [Related]  

  • 4.
    Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
    Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nesprin1 deficiency is associated with poor prognosis of renal cell carcinoma and resistance to sunitinib treatment.
    Fukushima T; Kobatake K; Miura K; Takemoto K; Yamanaka R; Tasaka R; Kohada Y; Miyamoto S; Sekino Y; Kitano H; Goto K; Ikeda K; Goriki A; Hieda K; Kaminuma O; Hinata N
    Oncology; 2024 Mar; ():. PubMed ID: 38442705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of
    Gong Z; Wu X; Guo Q; Du H; Zhang F; Kong Y
    Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35886066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
    Zhang H; Liu Y; Wang B; Wang C
    BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.
    Ti W; Wei T; Wang J; Cheng Y
    Front Immunol; 2022; 13():947712. PubMed ID: 35935970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures.
    Tong Y; Yu Y; Zheng H; Wang Y; Xie S; Chen C; Lu R; Guo L
    Front Oncol; 2021; 11():776824. PubMed ID: 34976818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
    Ran X; Xiao J; Zhang Y; Teng H; Cheng F; Chen H; Zhang K; Sun Z
    Ther Adv Med Oncol; 2020; 12():1758835920977117. PubMed ID: 33425025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
    Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
    Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 15. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
    Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
    McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
    Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
    Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
    Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of prognostic oncogene filaggrin (
    Chen L; Huang X; Xiong L; Chen W; An L; Wang H; Hong Y; Wang H
    Transl Androl Urol; 2022 Oct; 11(10):1419-1432. PubMed ID: 36386263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer.
    Chen J; Apizi A; Wang L; Wu G; Zhu Z; Yao H; Chen G; Shi X; Shi B; Tai Q; Shen C; Zhou G; Wu L; He S
    J Gastrointest Oncol; 2021 Oct; 12(5):2244-2259. PubMed ID: 34790389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.
    Gan J; Zhang H
    Transl Cancer Res; 2020 Aug; 9(8):4800-4810. PubMed ID: 35117843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.